Bulletin
Investor Alert

Sanofi

OTC: SNYNF

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Sanofi

Market closed

 --Quotes are delayed by 20 min

Mar 27, 2023, 1:52 p.m.

SNYNF
/zigman2/quotes/205505035/delayed

$

107.05

Change

+2.05 +1.95%

Volume

Volume 776

Quotes are delayed by 20 min

/zigman2/quotes/205505035/delayed

Previous close

$ 105.00

$ 107.05

Change

+2.05 +1.95%

Day low

Day high

$105.99

$107.05

Open

52 week low

52 week high

$73.31

$112.50

Open

Company Description

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specia...

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Valuation

P/E Current

14.39

P/E Ratio (with extraordinary items)

14.40

P/E Ratio (without extraordinary items)

13.44

Price to Sales Ratio

2.63

Price to Book Ratio

1.50

Price to Cash Flow Ratio

10.73

Enterprise Value to EBITDA

9.36

Enterprise Value to Sales

2.99

Total Debt to Enterprise Value

0.17

Efficiency

Revenue/Employee

469,538.00

Income Per Employee

91,413.00

Receivables Turnover

4.19

Total Asset Turnover

0.35

Liquidity

Current Ratio

1.42

Quick Ratio

1.05

Cash Ratio

0.53

Profitability

Gross Margin

63.13

Operating Margin

23.33

Pretax Margin

24.24

Net Margin

19.47

Return on Assets

6.78

Return on Equity

11.67

Return on Total Capital

10.68

Return on Invested Capital

9.34

Capital Structure

Total Debt to Total Equity

28.36

Total Debt to Total Capital

22.10

Total Debt to Total Assets

16.74

Long-Term Debt to Equity

22.41

Long-Term Debt to Total Capital

17.46

Officers and Executives

Name Age Officer Since Title
Mr. Serge Weinberg 70 2009 Director
Mr. Paul Hudson 53 2019 Chief Executive Officer
Mr. Jean-Baptiste Chasseloup de Chatillon 57 2018 Chief Financial Officer & Executive Vice President
Dr. Dietmar P. Berger - 2019 Chief Medical Officer & Global Head-Development
Mr. Nestle Frank - 2016 Global Head-Immunology Therapeutic Research Area

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
12/22/2022 Emile Voest
500   Acquisition at $91.34 per share. 45,670
09/23/2022 Frédéric Oudéa
320   Acquisition at $78 per share. 24,960
09/06/2022 Carole Gabriella Ferrand
1   Acquisition at $80.62 per share. 80
12/22/2021 Barbara Lavernos
500   Acquisition at $87.7 per share. 43,850
12/22/2021 Barbara Lavernos
500   Acquisition at $87.7 per share. 43,850
11/18/2020 Rachel Duan
601   Acquisition at $85.63 per share. 51,463
11/18/2020 Rachel Duan
132   Acquisition at $85.62 per share. 11,301
11/18/2020 Rachel Duan
267   Acquisition at $85.5 per share. 22,828
11/12/2020 Lise Kingo
1,000   Acquisition at $85.2 per share. 85,204
02/21/2020 Sanofi
96,700   Acquisition at $93.07 per share. 8,999,665
02/20/2020 Sanofi
84,000   Acquisition at $93.78 per share. 7,877,830
02/19/2020 Sanofi
60,000   Acquisition at $94.29 per share. 5,657,406
02/18/2020 Sanofi
27,700   Acquisition at $92.45 per share. 2,560,809
/news/latest/company/us/snynf

MarketWatch News on SNYNF

  2. video content The New Doctor in the House: Consolidation

    9:46 a.m. Feb. 1, 2011

    - Barrons.com

  3. Your Money: Pros, cons of paying taxes with a credit card

    1:14 p.m. March 14, 2000

    - CBS.MarketWatch.com

  4. Retail sales roar ahead in February

    12:48 p.m. March 14, 2000

    - CBS.MarketWatch.com

  5. Clueless Investor: Web making muni bonds more accessible to individuals

    11:55 a.m. March 14, 2000

    - CBS.MarketWatch.com

  6. World Markets: Nikkei surrenders morning session's rebound

    3:15 a.m. March 14, 2000

    - Mariko Ando

  7. Michael J. Bazdarich: No need to worry about the 'wealth effect'

    10:13 p.m. March 13, 2000

    - CBS.MarketWatch.com

  8. Washington schedule for March 13-19

    6:44 p.m. March 13, 2000

    - CBS.MarketWatch.com

  9. Joe Battipaglia: Economic data will show that inflation is tame

    12:29 p.m. March 13, 2000

    - CBS.MarketWatch.com

  10. Washington schedule for March 13-19

    1:09 p.m. March 11, 2000

    - CBS.MarketWatch.com

/news/nonmarketwatch/company/us/snynf

Other News on SNYNF

  1. Sanofi wins EU nod for Dupixent to include new skin condition

    8:00 a.m. Nov. 11, 2022

    - Seeking Alpha

  2. Biogen names former Sanofi head Chris Viehbacher as new CEO

    9:18 a.m. Nov. 10, 2022

    - Seeking Alpha

  4. Sanofi: What Has Happened?

    12:38 p.m. Nov. 9, 2022

    - Seeking Alpha

  5. Kymera: Upcoming Trial Data Will Make Or Break The Company

    12:46 p.m. Nov. 8, 2022

    - Seeking Alpha

  7. Pfizer: Q3 Earnings Review - Planning For Life After COVID

    2:17 p.m. Nov. 3, 2022

    - Seeking Alpha

  12. Sanofi SA (SNY) Q3 2022 Earnings Call Transcript

    3:40 p.m. Oct. 28, 2022

    - Seeking Alpha

  13. Regeneron slips as Raymond James downgrades on Eylea concerns

    7:41 a.m. Oct. 26, 2022

    - Seeking Alpha

  15. DTH: Beaten By Inflation

    7:33 a.m. Oct. 3, 2022

    - Seeking Alpha

  16. BioMarin Pharmaceutical: Leader In Rare Disease Innovation

    11:11 p.m. Oct. 2, 2022

    - Seeking Alpha

  18. Exploding EV Competition Could Send Tesla Under $100

    9:22 a.m. Sept. 14, 2022

    - Seeking Alpha

  19. Sanofi: A Nightmarish August To Take Advantage Of

    5:00 p.m. Sept. 9, 2022

    - Seeking Alpha

  20. New York declares polio emergency to improve vaccinations

    12:20 p.m. Sept. 9, 2022

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Sanofi

46, avenue de la Grande Armée

Paris, Ile-de-France 75017

Phone

33 153774000

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

01/0002

View SEC Filings

Revenue

$43.00B

Net Income

$8.37B

2022 Sales Growth

13.9%

Employees

-

Annual Report for SNYNF

/news/pressrelease/company/us/snynf

Press Releases on SNYNF

Link to MarketWatch's Slice.